About: Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens
Creator	Dobaño, Carlota Moncunill, Gemma Aguilar, Ruth Barrios, Diana Carolis, Carlo Jiménez, Alfons Mayor, Alfredo Santamaria, Pere Santano, Rebeca Vidal, Marta García-Basteiro, Alberto Carmona-Torre, Francisco Chi, Jordi Izquierdo, Luis Martínez De Aguirre, Paula Melero, Natalia Parras, Daniel Reina, Gabriel Ruiz-Olalla, Gemma Serra, Pau
Source	BioRxiv
abstract	Reliable serological tests are required to determine the prevalence of antibodies against SARS-CoV-2 antigens and to characterise immunity to the disease in order to address key knowledge gaps in the context of the COVID-19 pandemic. Quantitative suspension array technology (qSAT) assays based on the xMAP Luminex platform overcome the limitations of rapid diagnostic tests and ELISA with their higher precision, dynamic range, throughput, miniaturization, cost-efficacy and multiplexing capacity. We developed three qSAT assays to detect IgM, IgA and IgG to a panel of eight SARS-CoV-2 antigens including spike (S), nucleoprotein (N) and membrane (M) protein constructs. The assays were optimized to minimize processing time and maximize signal to noise ratio. We evaluated the performance of the assays using 128 plasmas obtained before the COVID-19 pandemic (negative controls) and 115 plasmas from individuals with SARS-CoV-2 diagnosis (positive controls), of whom 8 were asymptomatic, 58 had mild symptoms and 49 were hospitalized. Pre-existing IgG antibodies recognizing N, M and S2 proteins were detected in negative controls suggestive of cross-reactive to common cold coronaviruses. The best performing antibody isotype/antigen signatures had specificities of 100% and sensitivities of 94.94% at ≥14 days since the onset of symptoms and 96.08% at ≥21 days since the onset of symptoms, with AUC of 0.992 and 0.999, respectively. Combining multiple antibody markers as assessed by qSAT assays has the highest efficiency, breadth and versatility to accurately detect low-level antibody responses for obtaining reliable data on prevalence of exposure to novel pathogens in a population. Our assays will allow gaining insights into antibody correlates of immunity required for vaccine development to combat pandemics like the COVID-19.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.11.147363
has license	biorxiv
sha1sum (hex)	0a815bbe7da1480049167dd1413b5190feaefb38
schema:url	https://doi.org/10.1101/2020.06.11.147363
resource representing a document's title	Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens
schema:publication	bioRxiv
resource representing a document's body	covid:0a815bbe7da1480049167dd1413b5190feaefb38#body_text
is schema:about of	named entity 'symptoms' named entity 'days' named entity 'efficiency' named entity 'overcome' named entity 'diagnosis' named entity 'IgG' named entity 'suspension' named entity 'constructs' named entity 'assays' named entity 'SARS-CoV-2' named entity 'CONTROLS' named entity 'PROTEIN ' named entity 'IGM' named entity 'dynamic range' named entity 'antibody' named entity 'antibody' named entity 'recognizing' named entity 'optimized' named entity 'pathogens' named entity 'COVID-19' named entity 'combat' named entity 'insights' named entity 'specificities' named entity 'development' named entity 'antigens' named entity 'IgA' named entity 'ratio' named entity 'suggestive' named entity 'multiple' named entity 'based' named entity 'rapid diagnostic tests' named entity 'antibody' named entity 'SARS-CoV-2' named entity 'antibody' named entity 'COVID-19 pandemic' named entity 'nucleoprotein' named entity 'IgA' named entity 'antigens' named entity 'positive controls' named entity 'IgG antibodies' named entity 'nucleoprotein' named entity 'antigens' named entity 'onset' named entity 'IgM' named entity 'sensitivity and specificity' named entity 'protein' named entity 'HKU1' named entity 'IgG antibodies' named entity 'correlation' named entity 'serological' named entity 'economy of scale' named entity 'antibody reactivity' named entity 'Luminex' named entity 'serology' named entity 'polyclonal' named entity 'N-term' named entity 'qSAT' named entity 'Secondary antibodies' named entity 'IgA' named entity 'IgG' named entity 'Foundation for Innovative New Diagnostics' named entity 'asymptomatic' named entity 'COOH' named entity 'secondary antibody' named entity 'antibodies'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software